Pages that link to "Q57987677"

The following pages link to Azucena Esparís-Ogando (Q57987677):

Displaying 31 items.

• Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. (Q24531403) (← links)
• Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2 (Q24538180) (← links)
• Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer (Q30582030) (← links)
• Bortezomib is an efficient agent in plasma cell leukemias (Q33364213) (← links)
• ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy (Q33476874) (← links)
• Therapeutic potential of ERK5 targeting in triple negative breast cancer (Q34956816) (← links)
• ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. (Q36879241) (← links)
• Neuregulins and cancer. (Q37179990) (← links)
• Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target (Q37182453) (← links)
• Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies (Q37564335) (← links)
• ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. (Q38745576) (← links)
• Targeting the EGF/HER Ligand-Receptor System in Cancer. (Q38899794) (← links)
• Potent antimyeloma activity of a novel ERK5/CDK inhibitor (Q39175113) (← links)
• Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. (Q39196178) (← links)
• The nicotinic receptors in the nervous system (Q39553325) (← links)
• Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. (Q39959245) (← links)
• Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin (Q40390398) (← links)
• Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. (Q40740565) (← links)
• Stimulation of cleavage of membrane proteins by calmodulin inhibitors (Q40891936) (← links)
• Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase (Q41967579) (← links)
• The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. (Q42131728) (← links)
• Multifunctional role of Erk5 in multiple myeloma (Q45251392) (← links)
• The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. (Q46528752) (← links)
• The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. (Q54325437) (← links)
• MEK5 promotes lung adenocarcinoma (Q64087248) (← links)
• The alpha-bungarotoxin receptor purified from a human neuroblastoma cell line: biochemical and immunological characterization (Q69410331) (← links)
• Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme (Q73204078) (← links)
• Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms (Q74673079) (← links)
• Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis (Q79816809) (← links)
• Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer (Q80548331) (← links)
• Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway (Q92127095) (← links)